A Comparison of Orlistat Use in a Veteran Population: A Pharmacist-Managed Pharmacotherapy Weight-Loss Clinic Versus Standard Medical Care

Journal of Pharmacy Technology

Volumn 19, Issue 6, 2003, Pages 343-348

  Graham, Maqual R ^a,b   Landgraf, Chelsea G ^b,c   Lindsey, Cameron C ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Phelps County Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DYSLIPIDEMIA; DYSPEPSIA; FECES INCONTINENCE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; MEDICAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OILY DISCHARGE; PATIENT CARE; PATIENT COUNSELING; PHARMACIST; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0347511811     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250301900601     Document Type: Review

References (23)

1. Rao SV, Donahue M, Pi-Sunyer FX, Fuster V. Obesity as a risk factor in coronary artery disease. Am Heart J 2001;142:1102-7.
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288: 1723-7.
3. National Heart, Lung and Blood Institute in cooperation with the National Institutes of Diabetes and Digestive and Kidney Disease. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH publication no. 98-4083. Bethesda, MD: National Institutes of Health, 1998.
4. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitory, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999;69: 1108-16.
5. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-73.
6. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-32.
7. Package insert. Xenical (orlistat). Nutley, NJ: Roche Laboratories, September 2000.
8. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obesity 2000;24:306-13.
9. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halstead CH, Heber D. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
10. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22:738-47.
11. Chiquette E, Amato MC, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158: 1641-7.
12. Dong BJ. Pharmacist involvement in a thyroid clinic. Am J Hosp Pharm 1990;47:356-61.
13. Morreale AP. Pharmacist-managed Helicobacter pylori clinic. Am J Health Syst Pharm 1995;52:183-5.
14. Ellis SL, Carter BL, Malone DC, Bullups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Pharmacotherapy 2000;20:1508-16.
15. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother 2002;36:892-904. DOI 10.1345/aph.1A158
16. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41.
17. Irons BK, Lenz RJ, Anderson SL, Wharton BL, Habeger B, Anderson HG. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-300.
18. Gong C, Hasson NK, Lum BL. Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm 1999;5:511-5.
19. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharmacol Ther 1988;44:540-5.
20. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-8.
21. Package insert. Avandia (rosiglitazone). Research Triangle Park, NC: GlaxoSmithKline, May 2002.
22. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
23. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.